PMID- 22544446
OWN - NLM
STAT- MEDLINE
DCOM- 20140204
LR  - 20120814
IS  - 1545-1097 (Print)
IS  - 1545-1097 (Linking)
VI  - 11
IP  - 4
DP  - 2012 Jul-Aug
TI  - Diarrhea associated with lopinavir/ritonavir-based therapy: results of a 
      meta-analysis of 1469 HIV-1-infected participants.
PG  - 252-9
LID - 10.1177/1545109712442984 [doi]
AB  - BACKGROUND: Antiretroviral therapy is associated with adverse events (AEs). The 
      most frequently reported AE associated with lopinavir/ritonavir (LPV/r) 
      containing regimens is diarrhea. The objective of this meta-analysis is to 
      describe the incidence, prevalence, and duration of diarrhea in individuals 
      taking LPV/r. METHODS: This is a meta-analysis of Abbott-conducted clinical 
      trials. Inclusion criteria included prospective randomized clinical trials with 
      the LPV/r tablet formulation and had AE data (moderate/severe diarrhea) available 
      through 48 weeks of treatment. RESULTS: Three trials (total 1469 participants) 
      met the inclusion criteria. In all, 11.2% of participants reported 
      moderate/severe diarrhea by week 8, with median time to resolution of 7.4 weeks. 
      The overall 48-week incidence of moderate/severe diarrhea was 15.5%. The 
      discontinuation rate due to moderate/severe diarrhea was 1.3%. CONCLUSIONS: 
      Moderate/severe diarrhea occurred in less than 1 in 6 participants taking LPV/r, 
      typically started in the first 8 weeks of treatment and infrequently resulted in 
      premature discontinuation.
FAU - Wegzyn, Colleen M
AU  - Wegzyn CM
AD  - 1Abbott, Abbott Park, IL, USA.
FAU - Fredrick, Linda M
AU  - Fredrick LM
FAU - Stubbs, Roxann O
AU  - Stubbs RO
FAU - Woodward, William C
AU  - Woodward WC
FAU - Norton, Michael
AU  - Norton M
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20120427
PL  - United States
TA  - J Int Assoc Physicians AIDS Care (Chic)
JT  - Journal of the International Association of Physicians in AIDS Care (Chicago, 
      Ill. : 2002)
JID - 101185740
RN  - 0 (Anti-HIV Agents)
RN  - 0 (Antidiarrheals)
RN  - 0 (Drug Combinations)
RN  - 2494G1JF75 (Lopinavir)
RN  - O3J8G9O825 (Ritonavir)
SB  - IM
MH  - Anti-HIV Agents/*adverse effects
MH  - Antidiarrheals/therapeutic use
MH  - Diarrhea/*chemically induced/drug therapy/*epidemiology
MH  - Drug Combinations
MH  - Drug Therapy, Combination
MH  - HIV Infections/*drug therapy/virology
MH  - *HIV-1
MH  - Humans
MH  - Incidence
MH  - Lopinavir/*adverse effects
MH  - Prevalence
MH  - Risk Factors
MH  - Ritonavir/*adverse effects
EDAT- 2012/05/01 06:00
MHDA- 2014/02/05 06:00
CRDT- 2012/05/01 06:00
PHST- 2012/05/01 06:00 [entrez]
PHST- 2012/05/01 06:00 [pubmed]
PHST- 2014/02/05 06:00 [medline]
AID - 1545109712442984 [pii]
AID - 10.1177/1545109712442984 [doi]
PST - ppublish
SO  - J Int Assoc Physicians AIDS Care (Chic). 2012 Jul-Aug;11(4):252-9. doi: 
      10.1177/1545109712442984. Epub 2012 Apr 27.